Gene Expression Nebulas
基于标准化流程分析的转录图谱综合数据库

Gene Expression Nebulas

多物种转录图谱整合数据库

PRJNA487220: Molecular Signatures of Multiple Myeloma Progression through Single Cell RNA-Seq

来源: NCBI / GSE118900
提交时间: Aug 22 2018
释放时间: Nov 17 2018
最后更新时间: Mar 27 2019

概要: Multiple myeloma (MM) is a malignant plasma cell disorder with well-defined clonal genetic/cytogenetic abnormalities. However, cellular heterogeneity is a key factor in MM progression, therapeutic decision, and response to treatment. Single cell whole transcriptome profiling (scRNA-Seq) offers an opportunity to dissect this molecular heterogeneity during MM progression to better understand the disease and guide rational therapy. Here, we examined 597 CD138 positive cells from 15 patients at different stages of MM progression using scRNA-Seq. We selected 790 genes based on a Coefficient of Variation (CV) approach which organized cells into four clusters (L1-L4) based on unsupervised clustering. Plasma cells from each patient contained a mixed population of plasma cells at different state of aggressiveness based on gene expression signature reflecting the inter-cellular heterogeneous nature of MM. Cells in the L1 group is characterized by low level expression of genes involved in the oxidative phosphorylation, Myc targets, and mTORC1 signaling pathway having most cells from MGUS patients (p < 1.2x10-14). In contrast, low level of these genes in L1 group increased progressively and were the highest in the L4 group containing only cells from high-risk MM patients with t(4;14) translocations. Furthermore, 44 genes consistently overexpressed by pair-wised comparisons of the four groups strongly associated with a reduced overall survival in MM patients (APEX trial, p < 0.0001; Hazard Ratio (HR), 1.83; 95% CI, 1.33 to 2.52), particularly those in the bortezomib treated group (p < 0.0001; HR, 2.00; 95% CI, 1.39 to 2.89). No survival significance was observed for the dexamethasone treated group. Our study at the resolution of single cells showed that there is a mixed population of cells in each patient at different stages of MM progression and these cells can be organized into four different subgroups (L1 to L4). Consistent overexpression of the 44 genes from L1 to L4 groups is associated with patient outcome and treatment response. Our results show that oxidative phosphorylation, Myc target, and mTORC1 signaling genes are significant pathways for MM progression and affect MM prognosis and treatment stratification.

项目整体设计: 597 single cell libraries passed QC and were included in the downstream analysis

GEN 数据集:
GEND000050
测序方法:
物种:
组织:
健康状况:
方案
生长方案: -
处理方案: -
提取方案: Bone marrow aspirates were collected from 15 patients after informed consent and subjected to ACK lysis and mononuclear cell isolation. Plasma cells were separated by positive selection using CD138 coated magnetic beads (MACS; Miltenyi Biotec, CA) in a RoboSep system (STEMCELL Technology, Canada). CD138 positive cells were examined using Vi-CELL XR (Beckman Coulter, CA) to determine cell number, viability and average size. A microfluidic mRNA-Seq chip (Fluidigm, CA) was used for capturing cells from each sample at a concentration of 500ells/l and run in the Fluidigm C1 system to generate double stranded cDNA using SMARTer Ultra Low RNA kit for Illumina (Takara, CA). All samples were assessed for cell capture in a C1 chip by direct observation under a microscope and for cDNA quality using Fragment Analyzer (HS Large Fragment kit, Advanced Analytical Technologies, IA).
建库方案: -
测序信息
分子类型: poly(A)+ RNA
库的片段类型: PAIRED
库的链类型: -
测序平台: ILLUMINA
测序仪型号: Illumina HiSeq 2500
链特异性: Unspecific
样本
基本信息:
样本描述:
生物条件:
实验变量:
方案:
测序信息:
质量评估:
数据来源 GEN样本编号 GEN数据集编号 系列编号 项目编号 样本编号 样本名称 生物样本编号 样本访问号 实验访问号 释放时间 提交时间 最后更新时间 物种 种族 族裔 年龄 年龄单位 性别 来源名称 组织 细胞类型 细胞亚型 细胞系 疾病 疾病状态 发育阶段 突变/变异 表型 Condition Detail 生长方案 处理方案 提取方案 建库方案 分子类型 库的片段类型 链特异性 库的链类型 加标(Spike-In) 测序方法 测序平台 测序仪型号 细胞数 测序片段数 碱基数 平均测序片段长度_1 平均测序片段长度_2 唯一比对率 多重比对率 覆盖度
文章
Molecular signatures of multiple myeloma progression through single cell RNA-Seq.
Blood cancer journal . 2019-01-03 [PMID: 30607001]